• Home
  • 1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results.

1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results.

Author List
T. Jindal, H. Han, P.S. Deshmukh, I. De Kouchkovsky, D. Kwon, H.T. Borno, V.S. Koshkin, A. Desai, R. Bose, J. Chou, T. Friedlander, E.J. Small, A. Angelidakis, M.S. Johnson, S. Feng, A. Patnaik, L. Fong, J. Alumkal, R. Aggarwal
Publication
Annals of Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/425026006
Publication Year
2022
Publication Title
T. Jindal, H. Han, P.S. Deshmukh, I. De Kouchkovsky, D. Kwon, H.T. Borno, V.S. Koshkin, A. Desai, R. Bose, J. Chou, T. Friedlander, E.J. Small, A. Angelidakis, M.S. Johnson, S. Feng, A. Patnaik, L. Fong, J. Alumkal, R. Aggarwal. 1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results. Annals of Oncology. 2022 Sep 1; 33:s1187.